• Health
  • Design
  • Research

Creating a clear path for your signals

Reinventing clinically validated electrodes for faster, easier
and more user friendly applications in the ECG space

Show me more


Meet SmartMedics.
Making your biosignals transparent

SmartMedics created the first-on-market simultaneous 18-lead ECG patch with a dedicated device and mobile app. The patch is wireless, radiolucent and applied in under 15 seconds.
SmartMedics’ mission is to detect cardiac abnormalities, for use in home monitoring and cardiac tele-rehabilitation, while our future lies in algorithm development.

What we do

Our services

SmartMedics is reinventing ECG electrodes using our solutions for wearable health monitoring
with algorithms to analyze each and every result with the lowest margin of error.

  • Design

    Comfortable and flexible mobile health devices designed to monitor your biosignals on a dedicated smartphone app.

  • Research

    In-house material testing to achieve user-friendly quality in our multi-lead patches .

  • Laboratory

    Continuous innovation with our on-site lab, housing top of the line equipment.

  • Analysis

    Developing AI algorithms to analyze your ECG signals and offer real-time feedback, in the hospital or at-home.

Our laboratory

Sensors & Signals

SmartMedics lab is equipped with facilities for screen printing, material preparation, UV and thermal curing, as well as an examination area to test our multi-lead ECG electrode patches.



SmartMedics is a privately owned digital healthcare company with operations in Warsaw, Poland.

Our team consists of experts in R&D, design, engineering, data science, software, quality and healthcare professionals with years of relevant clinical experience.


  • Adrian MaciejewskiMD

    CEO & Co-Founder

  • Łukasz KołtowskiMD, PhD

    CMEDO & Co-Founder

  • Grzegorz WróblewskiPhD

    CRO & Co-Founder

Supervisory board

  • Kreske Nickelsen

    Chairman Of The Supervisory Board

  • Marek OrłowskiMD

    Member Of The Supervisory Board

  • Marcin Gołębicki

    Member Of The Supervisory Board


Recent news

  • 27/12/2017

    Introducing Kreske Nickelsen, Chairman of our Supervisory Board

    We have the pleasure to announce the Chairman of our Supervisory Board, Kreske Nickelsen. Ms Nickelsen is a venture capital professional with more than 18 years of supervisory board and investment experience in companies based all over Europe. Before JPIF, Ms Nickelsen was a partner at Aescap, a life science venture capital fund based in Amsterdam, and before that a director at 3i Group plc in London. She holds an MBA from INSEAD (France) and a Masters in Biology from Philipps University Marburg (Germany)

  • 27/12/2017

    SmartMedics got funding!

    We are excited to announce that we signed our investment agreement with Joint Polish Investment Fund (JPIF).
    SmartMedics raised PLN 7,0 million ($2.0 million) for the development and commercialisation of our products.

    Make your biosignals transparent!

  • 27/12/2017

    Introducing Marcin Golebicki as a new member of our Supervisory Board.

    We have the pleasure to announce a new member of our Supervisory Board, Marcin Golebicki. Mr. Golebicki was Vice President of St. Jude Medical (SJM) responsible for all business activities in 58 countries in Eastern Europe, Central Asia, Middle East and Africa. Since on board, he opened office in Serbia, Russia and Hungary. Responsible for acquisitions totalling 30 million USD. Mr. Golebicki implemented successful reorganization of the EEMEA region. He is primarily responsible for the successful Abbott acquisition in emerging markets. He hold an MBA from Minnesota University and has completed the Post Graduate Advanced Management Program from Harvard University.

  • 27/12/2017

    Introducing Marek Orłowski, our Supervisory Board Member

    We have the pleasure to announce a new member of our Supervisory Board, Dr.Marek Orłowski. Dr. Orłowski was co-founder of Nepentes SA, a manufacturer and supplier of pharmaceuticals. In 1997 IPO on WSE and in 2010 Sale to Sanofi-Aventis for about €106M. Since 2010 active as business angel investing in life-science companies in Poland and abroad.